POL F. BOUDES, M.D. - Corporate Board Profile

Protalix BioTherapeutics, Inc.

Filing Date	Source Excerpt
2020-04-15	Pol F. Boudes, M.D. Dr. Boudes joined our Board of Directors in January 2020. ... Pol F. Boudes, M.D. and Gwen A. Melincoff joined the Board of Directors effective January 1, 2020. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2019. ... Pol F. Boudes, M.D. is not listed in the non-employee directors compensation table.
2021-06-04	Pol F. Boudes, M.D. Dr. Boudes joined our Board of Directors in January 2020. ... Fees Earned or Paid in Cash ($): 40,000, Option Award(s) ($): 54,591, Total ($): 94,591.
2021-09-30	Pol F. Boudes, M.D. Consists of 40 outstanding shares of our common stock and 17,500 shares of our common stock issuable upon exercise of outstanding options
2022-04-29	Pol F. Boudes, M.D. Dr. Boudes joined our Board of Directors in January 2020. He is a senior physician and chief medical officer with more than 25 years of experience in research and development, with a special emphasis on orphan drugs and translational medicine. In March 2020, Dr. Boudes was appointed Chief Medical Officer of Galectin Therapeutics Inc. (NASDAQ:GALT). He also serves as a research and development consultant. From April 2014 through October 2019, he served as the Chief Medical Officer of CymaBay Therapeutics, Inc. (Nasdaq:CBAY) where he led the development of treatments for rare liver diseases. Dr. Boudes was also Chief Medical Officer at Amicus Therapeutics Inc. (Nasdaq:FOLD) from 2009 to 2013 where he was instrumental in the development of migalastat (Galafold®) for the treatment of Fabry disease, as well as treatments for Pompe disease and Gaucher disease. He has served in various roles at Berlex Laboratories (acquired by Bayer HealthCare Pharmaceuticals), Wyeth-Ayerst Research, Hoffmann-La Roche and Pasteur-Merieux Serums & Vaccines. Dr. Boudes holds an M.D. from the University of Aix-Marseilles, France and has specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases. We believe Dr. Boudes’ qualifications to serve on our Board of Directors include his vast experience and knowledge of the research and development of pharmaceuticals.
2023-05-18	Pol F. Boudes, M.D. Dr. Boudes joined our Board of Directors in January 2020. He is a senior physician and chief medical officer with more than 25 years of experience in research and development, with a special emphasis on orphan drugs and translational medicine. In March 2020, Dr. Boudes was appointed Chief Medical Officer of Galectin Therapeutics Inc. (NASDAQ:GALT). He also serves as a research and development consultant. From April 2014 through October 2019, he served as the Chief Medical Officer of CymaBay Therapeutics, Inc. (Nasdaq:CBAY) where he led the development of treatments for rare liver diseases. Dr. Boudes was also Chief Medical Officer at Amicus Therapeutics Inc. (Nasdaq:FOLD) from 2009 to 2013 where he was instrumental in the development of migalastat (Galafold®) for the treatment of Fabry disease, as well as treatments for Pompe disease and Gaucher disease. He has served in various roles at Berlex Laboratories (acquired by Bayer HealthCare Pharmaceuticals), Wyeth-Ayerst Research, Hoffmann-La Roche and Pasteur-Merieux Serums & Vaccines. Dr. Boudes holds an M.D. from the University of Aix-Marseilles, France and has specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases. We believe Dr. Boudes’ qualifications to serve on our Board of Directors include his vast experience and knowledge of the research and development of pharmaceuticals.
2024-04-29	Pol F. Boudes, M.D. Dr. Boudes joined our Board of Directors in January 2020. ... The Board of Directors has determined that ... Dr. Boudes ... is an “independent director” ... The membership of each committee is as follows: Audit and Finance Committee Chairman: Shmuel “Muli” Ben Zvi, Ph.D.; Membership: Shmuel “Muli” Ben Zvi, Ph.D., Amos Bar Shalev and Aharon Schwartz, Ph.D. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2023. ... Fees Earned or Paid in Cash ($): 41,250; Option Award(s) ($): 38,660; All Other Compensation ($): 35,475; Total ($): 115,385.